killer cell lectin like receptor C4Genealiases: NKG2-F · NKG2F
Q-omics provides the consensus-scored KLRC4 profile across patient tissues and cancer cell-line models. KLRC4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, KLRC4 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, KLRC4 RNA expression shows 14,936 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, KIRC, and THYM as cancer lineages where KLRC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLRC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLRC4 survival associations across molecular data types. KLRC4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLRC4 RNA expression–survival associations across cancer types. High KLRC4 expression shows unfavorable associations in KIRC and UVM, but favorable associations in SKCM, HNSC, BLCA and LGG. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for KLRC4 RNA expression.
This table summarizes KLRC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KLRC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLRC4 shows lower tumor expression in LUSC, THCA, BRCA and COAD and higher tumor expression in KIRC and STAD. The KIRC box plot shows higher KLRC4 RNA expression in tumor versus normal tissue (log2 FC = +0.314, t-test p < 0.001).
This table shows molecular features associated with KLRC4 in patient tissues and cancer cell lines. In patient samples, KLRC4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLRC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_SCLC.
